UAB CFRC Core C: Clinical and Translational Core

UAB CFRC 核心 C：临床和转化核心

基本信息

批准号：
10673357
负责人：
Steven Mark Rowe
金额：
$ 15.2万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-04-01 至 2028-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10673357
关键词：
Acceleration Address Adult Alleles Animal Model Animals Basic Science Biological Assay Biomedical Research Calorimetry Cell model Cell physiology Cellular Assay Child Chlorides Clinical Clinical Research Clinical Sciences Clinical Trials Collaborations Complement Continuous Glucose Monitor Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Defect Delta F508 mutation Development Diagnostic Disease Dual-Energy X-Ray Absorptiometry Endocrine Endocrine system Endocrinology Environment Epithelial Cells Epithelium Erythrocytes Evaluation Faculty Feasibility Studies Fostering Frequencies Functional Imaging Functional disorder Funding Future Gastrointestinal tract structure Genetic Goals Hemolysis Host Defense Human Image In Vitro Individual Infection Inflammation Institution International Intestines Investigational Therapies Ion Transport Ketones Laboratories Link Lung Lung diseases Measurement Measures Metabolism Methods Monitor Mucociliary Clearance Mucous Membrane Mucous body substance Mutation Nose Nutritional Nutritional Study Observational Study Optical Coherence Tomography Organoids Outcome Outcome Measure Pathogenesis Pathway interactions Performance Pilot Projects Positioning Attribute Process Pulmonary Cystic Fibrosis Reagent Rectum Research Research Personnel Research Project Grants Resolution Resources Role Science Scientific Advances and Accomplishments Scientist Secure Senior Scientist Sinus Site Specimen Standardization Structure Supplementation Surface System Techniques Testing Tissues Training Translating Translational Research Translations United States National Institutes of Health Viscosity airway epithelium airway surface liquid base biobank clinical center clinical outcome measures clinical translation collaborative environment cystic fibrosis patients data management design experience gastrointestinal system gene therapy human subject human tissue improved in vivo innovation insight new therapeutic target next generation novel novel therapeutic intervention novel therapeutics nutrition physical property programs quality assurance real-time images rectal response sample collection tool translational therapeutics trial design

项目摘要

PROJECT SUMMARY/ABSTRACT The UAB P30 Research and Translation Core Center consolidates a large number of externally funded cystic fibrosis (CF) research programs on our campus, building an innovative environment to pursue, advance, and train in CF-related science. During the last funding period, the P30 made robust and important contributions to multiple UAB laboratories of our Research Base of over 70 investigators pursuing research relevant to CFTR modulation; CF pathogenesis; novel outcome measures for the genetic therapy era; infection and inflammation in the context of highly effective modulator therapy; and therapeutic translation for untreated CFTR mutations. By virtue of the NIH Center, translational research at our Institution has continued to accelerate in the past five years, as has the breadth of investigators. The richness of CF basic science at UAB has grown in parallel with this translational expansion, providing numerous opportunities to exploit in the next funding period, and the Center is strategically structured to take advantage of these opportunities. The P30 Center has allowed investigators at UAB and collaborating sites to improve understanding of CF disease mechanism and has furnished novel opportunities to aggressively apply this information towards experimental therapeutics, including genetic-based therapies that will continue to grow in emphasis. This NIH Center includes three Biomedical Research Cores that help to organize efforts of CF faculty towards the common and essential goal of helping individuals with CF and to train the next generation of CF leaders. The Cores include: Core A: Cell Model and Assay Core (GM Solomon and J Guimbellot, Co-PIs); Core B: Animal Models Core (DM Bedwell and S Birket, Co-PIs); and Core C: Clinical and Translational Core (SM Rowe and A Gaggar, Co-PIs). Each Core provides leading-edge assays, specialized reagents and techniques, and valued expertise. The P30 has also engaged new investigators through a Pilot and Feasibility mechanism integral to Center vitality and has a tight integration with the UAB Center for Clinical and Translational Science, enabling a robust training environment. In addition to providing a platform from which junior and senior scientists are brought into the field, Pilot Projects serve as a means of rapidly testing exciting advances, particularly from the perspective of clinical translation. Two Pilot and Feasibility Projects are in progress: Project 1: R Patel, PI. “Erythrocyte Hemolysis and Lung Disease in CF”; and Project 2: E Plaisance, PI. “Ketone Monoester Supplementation in CF: A Pilot and Feasibility Study”, capitalizing on the next era of innovative opportunities to transform the disease. Through these scientific initiatives, the P30 has added value to a collaborative environment for CF research at our Institution, and is well-positioned to continue in this capacity in the future, with a major focus on therapeutic translation.

项目概要/摘要 UAB P30研究与翻译核心中心整合了大量外部资助的囊性我们校园内的纤维化（CF）研究项目，建立一个创新的环境来追求、推进和在上一个资助期内，P30 为 CF 相关科学培训做出了强有力的重要贡献。我们研究基地的多个 UAB 实验室由 70 多名研究人员从事与 CFTR 相关的研究调节；CF 发病机制；基因治疗时代的新结果措施；在高效调节剂治疗的背景下；以及未经治疗的 CFTR 突变的治疗转化。借助 NIH 中心，我们机构的转化研究在过去五年中持续加速多年来，UAB 的 CF 基础科学的丰富性与研究人员的广度同步增长。这种转化扩张，为下一个资助期提供了大量的利用机会，并且中心的战略结构是为了利用这些机会。 P30 中心让 UAB 和合作中心的研究人员能够增进对 CF 的了解疾病机制，并为积极应用这些信息提供了新的机会实验疗法，包括基于基因的疗法，将继续受到 NIH 的重视。中心包括三个生物医学研究核心，帮助组织 CF 教师的努力帮助患有 CF 的个人并培训下一代 CF 领导者是共同和基本的目标。核心包括：核心 A：细胞模型和检测核心（GM Solomon 和 J Guimbellot，Co-PI）；核心 B：动物模型核心（DM Bedwell 和 S Birket，Co-PI）；以及核心 C：临床和转化核心（SM Rowe 和 A） Gaggar、Co-PI）每个核心都提供领先的专业试剂和检测技术以及有价值的技术。 P30 还通过试点和可行性机制聘请了新的调查人员。中心充满活力，并与 UAB 临床和转化科学中心紧密结合，使除了提供初级和高级科学家的平台外，还提供强大的培训环境。试点项目被带入现场后，成为快速测试进步的一种手段，特别是来自两个试点和可行性项目正在进行中：项目 1：R Patel，PI。 “CF 中的红细胞溶血和肺部疾病”；以及项目 2：E Plaisance，PI“酮单酯”。 CF 的补充：试点和可行性研究”，利用下一个时代的创新机会通过这些科学举措，P30 为协作增加了价值。我们机构有利于 CF 研究的环境，并且有能力在未来继续担任这一职位，主要关注治疗性翻译。